Puma Biotechnology, Inc. (NASDAQ:PBYI) Insider Jeffrey Jerome Ludwig Sells 9,437 Shares

Puma Biotechnology, Inc. (NASDAQ:PBYI) insider Jeffrey Jerome Ludwig sold 9,437 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total transaction of $29,726.55. Following the transaction, the insider now owns 108,951 shares in the company, valued at $343,195.65. This represents a 7.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Puma Biotechnology Stock Down 5.4 %

Shares of PBYI opened at $2.95 on Friday. Puma Biotechnology, Inc. has a 52 week low of $2.22 and a 52 week high of $7.73. The firm has a market cap of $144.81 million, a P/E ratio of 6.15 and a beta of 1.10. The firm’s 50-day simple moving average is $2.99 and its 200 day simple moving average is $2.97. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. The business had revenue of $80.50 million for the quarter, compared to analyst estimates of $71.32 million. During the same quarter in the prior year, the business earned $0.12 EPS. On average, analysts forecast that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a research note on Monday, December 23rd. StockNews.com lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 6th.

Institutional Trading of Puma Biotechnology

Institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC bought a new stake in Puma Biotechnology in the 3rd quarter valued at about $34,000. Franklin Resources Inc. bought a new stake in Puma Biotechnology in the 3rd quarter valued at about $41,000. Dynamic Technology Lab Private Ltd bought a new stake in Puma Biotechnology in the 3rd quarter valued at about $44,000. Patriot Financial Group Insurance Agency LLC boosted its holdings in Puma Biotechnology by 72.7% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 8,000 shares during the period. Finally, Royce & Associates LP boosted its holdings in Puma Biotechnology by 71.8% in the 3rd quarter. Royce & Associates LP now owns 20,165 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 8,427 shares during the period. Institutional investors own 61.29% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.